T1	Participants 294 380	64 adult patients with GBS for PE and IVIg treatment, respectively, and nerve function
T2	Participants 183 276	plasma exchange (PE) and intravenous immunoglobulin (IVIg) for Guillian-Barre Syndrome (GBS).
T3	Participants 1328 1336	patients
